New nucleoside analogs in the treatment of solid tumors

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Physiologic deoxynucleotides are crucial for accurate DNA replication, repair, and synthesis.
• Errors in DNA synthesis trigger apoptosis, a key target for anticancer therapies.
• Nucleoside analogs are designed to exploit these DNA synthesis and repair pathways.

Purpose of the Study:

• To review novel nucleoside analogs currently in clinical evaluation for solid tumor treatment.
• To explore the structure-based differences in metabolism and mechanisms of action of these analogs.
• To identify specific intracellular targets and diseases where these analogs are most effective.

Main Methods:

• Literature review of nucleoside analogs undergoing clinical trials.
• Analysis of biochemical pathways involved in DNA synthesis and repair.
• Examination of cytotoxicity mechanisms induced by nucleoside analogs.
• Investigation of potential interference with RNA synthesis.

Main Results:

• Several nucleoside analogs (tezacitabine, troxacitabine, DMDC, CNDAC, ECyD, clofarabine, decitabine) are in clinical trials for solid tumors.
• These analogs exhibit diverse mechanisms, including DNA synthesis inhibition and apoptosis induction.
• Some analogs also impact RNA synthesis, broadening their cytotoxic potential.
• Understanding structure-activity relationships aids in identifying optimal therapeutic applications.

Conclusions:

• Nucleoside analogs represent a promising class of anticancer agents targeting critical cellular processes.
• Ongoing clinical evaluations are essential for determining the efficacy and safety of these novel compounds.
• Further research into their specific targets and disease associations will optimize their clinical use.